A Review of Nelarabine in the Treatment of T-cell Lymphoblastic Leukemia/Lymphoma
Clinical Medicine. Therapeutics · 2009
DOI: 10.4137/cmt.s1954 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Medicine. Therapeutics, 2009. Verfasst von Francisco J. Hernandez-Ilizaliturri und 1 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Patients with relapsed/refractory T-cell acute lymphocytic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) have a dismal prognosis. Prior to the development of novel purine analogs, salvage chemotherapy was of limited efficacy. Nelarabine, and more recently, clofarabine and forodesine have demonstrated significant anti-tumor activity in relapsed/refractory T-ALL and T-LBL. As a single agent, nelarabine induces response rates in between 33% to 50% of adult or pediatric patients with T-ALL/T-LBL, respectively. On the other hand, limited activity was observed in mature T-cell neoplasms. Significant neurotoxicity has been the major obstacle for the further clinical development of nelarabine. Alternative dose-schedules for administration have been evaluated with some degree of success. Ongoing clinical studies are integrating nelarabine in the front-line chemotherapy regimens for patients with T-ALL/T-LBL in pediatric and young adult patients. The current work summarizes the pre-clinical and clinical evaluation of nelarabine, a chemotherapy agent whose development demonstrates that industry, government agencies, and academia can effectively collaborate together to improve the patient outcomes with highly resistant/refractory rare hematological malignancies.
Zitieren
APA
Hernandez-Ilizaliturri, F. J., & Czuczman, M. S. (2009). A Review of Nelarabine in the Treatment of T-cell Lymphoblastic Leukemia/Lymphoma. Clinical Medicine. Therapeutics. https://doi.org/10.4137/cmt.s1954
Vancouver
Hernandez-Ilizaliturri FJ, Czuczman MS. A Review of Nelarabine in the Treatment of T-cell Lymphoblastic Leukemia/Lymphoma. Clinical Medicine. Therapeutics. 2009. doi:10.4137/cmt.s1954
BibTeX
@article{HernandezIlizaliturri2009,
author = {Hernandez-Ilizaliturri, Francisco J. and Czuczman, Myron S.},
title = {A Review of Nelarabine in the Treatment of T-cell Lymphoblastic Leukemia/Lymphoma},
journal = {Clinical Medicine. Therapeutics},
year = {2009},
doi = {10.4137/cmt.s1954}
}
EUVIMED